Single Donor Plasmapheresis for COVID-19: An Experience from a Tertiary Care Hospital Based Blood Centre
Introduction: Corona Virus Disease-2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) became a global health problem since December 2019. No single treatment was found to be effective against COVID-19. Transfusion of COVID Convalescent Plasma (CCP) was found...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Pvt. Ltd.
2022-10-01
|
Series: | National Journal of Laboratory Medicine |
Subjects: | |
Online Access: | https://www.njlm.net/articles/PDF/2677/55562_CE_[Nik]_F(SHU)_PF1(SG_SHU)_Redo_PFA(SHU)_PN(SHU).pdf |
Summary: | Introduction: Corona Virus Disease-2019 (COVID-19) caused by
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2)
became a global health problem since December 2019. No single
treatment was found to be effective against COVID-19. Transfusion
of COVID Convalescent Plasma (CCP) was found to be a useful
and logistically feasible therapeutic strategy in COVID-19.
Aim: To study the feasibility of single donor plasmapheresis
for COVID-19, to analyse statistical significance of clinicodemographical data and biochemical parameters of convalescent
plasmapheresis donors and to further study the adverse reactions
and technical problems that occurred during the procedure of
single donor plasmapheresis.
Materials and Methods: A prospective observational study
was carried out over a period of 10 months from June 2020 to
March 2021. The study included 235 screened donors and 50
procedures for single donor plasmapheresis (SDPs). Donors were
selected as per the standard criteria given by Indian Council of
Medical Research (ICMR). All plasmapheresis procedures were
performed on an automated blood cell separator. The results
were tabulated and statistical analysis was performed using
Statistical Package for the Social Sciences (SPSS) software.
Results: Out of 235 prospective CCP donors, 164 (69.78%)
were found eligible. The causes of non eligibility donors were
unwillingness to donate, absence of SARS-CoV-2 antibody,
Transfusion Transmitted Disease (TTD) positivity, and improper
haematological parameters. Actual plasma donations were
carried out in 50 (21.27%) eligible donors. Therapeutically
needed amount of CCP (400 mL) could be collected from most
of the donors. Adverse reactions were seen in 4 (8%) donors.
Conclusion: Adequate amount of CCP could be collected
by single donor plasmapheresis with satisfactory technical
support. The procedure was well accepted by the prescreened
donors with minimum adverse reactions. |
---|---|
ISSN: | 2277-8551 2455-6882 |